They know there product doesnt work and there is no scientist evidence like they are suggesting
Asher MI, Garca-Marcos L, Pearce NE, Strachan DP
Pharmacotherapy for non-alcoholic fatty liver disease: Emerging targets and drug candidates
These include a history of pancreatitis, severe gastrointestinal conditions such as gastroparesis, gallbladder disease, and reduced kidney function, where dehydration from vomiting or diarrhea is the main concern
The catchy Broadway-inspired commercials may lead you to believe that Novo Nordisk is the clear leader between the two, but the reality is quite the opposite
With increasing competition and a broader range of available treatments, regulatory approvals are expected to play a pivotal role in driving growth in the glucagon like peptide 1 analogs market